When traditional animal models can't capture
how a new biomaterial really behaves

An early-stage biomaterials company developing a novel biomembrane scaffold material ran into a common problem: traditional animal testing doesn't reliably predict biocompatibility for genuinely new material classes. On top of the technical question, the company also needed a stronger, more differentiated technical story heading into its next financing round.

We applied organ-chip-based prediction as a complement to traditional evaluation methods, pairing it with regulatory science analysis to build a data package that's easier for regulators to accept. We also supported the client in preparing a peer-reviewed publication describing the approach — with the client as first author.

Nonclinical evaluation time dropped to roughly 12–15 months, compared with 18–24 months on the traditional path, with materially lower evaluation cost. The client also came away with a published, citable technical asset to support its own market and investor conversations.

Figures reflect an anonymized platform engagement, shared with client consent under our standard confidentiality practice. Specific client identity, product details, and commercial terms are withheld.